Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

KyungAh Im

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
JAMA Cardiology|May 1, 2018
Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical TrialBrian A Bergmark, Jacob A Udell, David A Morrow, et al.
Hepatology (Baltimore, Md.)|May 26, 2007
Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virusLeland J Yee, Yong-Ming Tang, David E Kleiner, et al.
Journal of the American College of Cardiology|February 7, 2024
Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary DiseaseDaniel J McClintick, Michelle L O'Donoghue, Gaetano M De Ferrari, et al.
Journal of the American College of Cardiology|January 30, 2016
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT TrialSabina A Murphy, Christopher P Cannon, Michael A Blazing, et al.
European Heart Journal|June 3, 2026
Safety of low lipoprotein(a) levels: the FOURIER trialBaris Gencer, Robert P Giugliano, Xinhui Ran, et al.
The New England Journal of Medicine|August 17, 2017
Cognitive Function in a Randomized Trial of EvolocumabRobert P Giugliano, François Mach, Kenton Zavitz, et al.
Circulation|February 22, 2019
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes MellitusThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
Lancet (London, England)|November 15, 2018
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
Circulation|August 29, 2022
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular DiseaseMichelle L O'Donoghue, Robert P Giugliano, Stephen D Wiviott, et al.
Journal of the American Heart Association|February 9, 2021
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial InfarctionGiulia Magnani, Diego Ardissino, KyungAh Im, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
JAMA Cardiology|May 1, 2018
Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical TrialBrian A Bergmark, Jacob A Udell, David A Morrow, et al.
Hepatology (Baltimore, Md.)|May 26, 2007
Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virusLeland J Yee, Yong-Ming Tang, David E Kleiner, et al.
Journal of the American College of Cardiology|February 7, 2024
Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary DiseaseDaniel J McClintick, Michelle L O'Donoghue, Gaetano M De Ferrari, et al.
Journal of the American College of Cardiology|January 30, 2016
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT TrialSabina A Murphy, Christopher P Cannon, Michael A Blazing, et al.
European Heart Journal|June 3, 2026
Safety of low lipoprotein(a) levels: the FOURIER trialBaris Gencer, Robert P Giugliano, Xinhui Ran, et al.
The New England Journal of Medicine|August 17, 2017
Cognitive Function in a Randomized Trial of EvolocumabRobert P Giugliano, François Mach, Kenton Zavitz, et al.
Circulation|February 22, 2019
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes MellitusThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
Lancet (London, England)|November 15, 2018
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThomas A Zelniker, Stephen D Wiviott, Itamar Raz, et al.
Circulation|August 29, 2022
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular DiseaseMichelle L O'Donoghue, Robert P Giugliano, Stephen D Wiviott, et al.
Journal of the American Heart Association|February 9, 2021
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial InfarctionGiulia Magnani, Diego Ardissino, KyungAh Im, et al.
Pageof 8